Recent advances and future directions in preclinical research of arginine-vasopressin (AVP) receptor blocker conivaptan in the context of stroke

Stroke is a major cause of mortality and permanent disability. The onset of stroke is followed by life-threatening pathophysiological responses including brain edema, elevation of intracranial pressure, disruption of blood-brain barrier (BBB), brain infarct and permanent tissue damage. Brain edema develops due to accumulation of water in intracellular and extracellular compartments of the brain, which causes an increase in brain volume and elevation of intracranial pressure. Conivaptan, a vasopressin (AVP) receptor blocker, reduces brain edema and BBB breakdown in mice after subarachnoid hemorrhage (SAH) (Hockel et al., 2012). In this study, authors use the model of endovascular puncture to induce SAH followed by intravenous delivery of a specific V1a receptor blocker. Monitoring of physiological parameters during the treatment revealed that the V1a receptor blocker can reduce intracranial pressure, rCBF, and mean arterial blood pressure and prevent re-bleeding after SAH. Thus, the prominent advantage of the V1a receptor blocking effect on cerebral vasculature after SAH may be relevant in the context of ischemic stroke. Another study by Rauen and colleagues shows that mice which lack V1a receptor are protected against secondary brain injury after traumatic brain injury (TBI) (Rauen et al., 2013). In this study V1a receptor knock-out mice exhibited smaller brain edema induced by controlled cortical impact (CCI), which was also confirmed by an improved neurological dysfunction. Therefore, targeting of V1a receptors is proven to be a promising strategy in therapeutic intervention against TBI-induced brain injury. Follow-up physiological studies are necessary to explore whether conivaptan is able to improve rCBF after stroke or TBI. It is likely that this unexplored feature of conivaptan can enhance its potential for future clinical trials of stroke and brain edema. A single case report in the literature demonstrated that conivaptan can be potentially useful as an alternative drug to treat brain edema after cerebrovascular accident (Hedna et al., 2014). In this case, a patient suffered a ruptured cerebral artery aneurysm which extended into the basilar circulation. Brain edema was detected in the midbrain and thalamic regions post-hemorrhage. After unsuccessful conventional anti-edema therapy, administration of conivaptan reduced brain edema in the previously swollen regions as well as clinical improvement. These results support the notion that this unexplored feature of conivaptan can enhance its potential for future clinical trials of stroke and brain edema. Therefore, conivaptan is able to improve rCBF after stroke or TBI. It is likely that this unexplored feature of conivaptan can enhance its potential for future clinical trials of stroke and brain edema. Follow-up physiological studies are necessary to explore whether conivaptan is able to improve rCBF after stroke or TBI. It is likely that this unexplored feature of conivaptan can enhance its potential for future clinical trials of stroke and brain edema. Therefore, conivaptan is able to improve rCBF after stroke or TBI. It is likely that this unexplored feature of conivaptan can enhance its potential for future clinical trials of stroke and brain edema. Therefore, conivaptan is able to improve rCBF after stroke or TBI. It is likely that this unexplored feature of conivaptan can enhance its potential for future clinical trials of stroke and brain edema. Therefore, conivaptan is able to improve rCBF after stroke or TBI. It is likely that this unexplored feature of conivaptan can enhance its potential for future clinical trials of stroke and brain edema. Therefore, conivaptan is able to improve rCBF after stroke or TBI. It is likely that this unexplored feature of conivaptan can enhance its potential for future clinical trials of stroke and brain edema. Therefore, conivaptan is able to improve rCBF after stroke or TBI.
studies are required to explore underlying molecular pathways of this anti-edema effect of the drug.

The molecular mechanisms of V1a receptor blocking effects of conivaptan have not been studied in the brain. However, we have demonstrated that the V2 blocking effect of conivaptan is responsible for excretion of excess water by the kidney and elevation of blood osmolality (Zeynalov et al., 2015), which could potentially help prevent development of brain edema. It has not been established whether V2 receptor exists in the brain. We also reported in our study that orally delivered tolvaptan, a selective V2 receptor blocker, has no beneficial role for post-ischemic brain edema. The oral administration route for tolvaptan, used according to the manufacturer's recommendation, produced the expected aquaretic effect and was sufficient to increase plasma sodium levels. However, tolvaptan failed to increase plasma osmolality overall (Zeynalov et al., 2015). This result suggests that osmolality per se may be important in the mechanisms involved in the genesis and/or resolution of cerebral edema. Based on our current results, we speculate that the V1a blocking component of conivaptan is perhaps crucial for protection against brain edema and BBB disruption, but the importance of the V2 blocking component of conivaptan requires further study.

It has been shown that the aquaporin-4 (AQP-4) in the brain plays an important role in reduction of brain edema and preservation of BBB after stroke (Zeynalov et al., 2008). AQP has a significant influence on the role of AQPs in water movement across membranes both in the brain (Liu et al., 2010) and the kidneys (Deen et al., 1994; Fenton and Moeller, 2008). The experimental studies of selective V1a receptor blockers in stroke, intracerebral hemorrhage (ICH), or TBI indicate that there is an association between AQP-4 expression and protection induced by these drugs (Liu et al., 2010; Manaenko et al., 2011; Kleindienst et al., 2013). In the study by Liu and colleagues, the authors use the filament stroke model (MCAO) in mice and the intracerebroventricular delivery route for V1a or V2 receptor blockers. The study reports that the V1a receptor blocker treatment reduced stroke-induced infarct and brain edema, and these beneficial effects were linked to an upregulation of AQP-4 expression in the brain. The intracerebroventricular treatment with V2 receptor blocker after stroke in mice failed to produce protective effects on infarct volume and brain edema. Manaenko and colleagues investigated the V1a receptor blocking effect on neurological outcomes after ICH in mice (Manaenko et al., 2011). ICH was induced by collagenase injection into the brain and followed by treatment with the experimental V1a receptor blocker SR49059. Neurobehavioral testing, evaluation of brain edema and BBB disruption suggested that the V1a receptor blocker is protective against collagenase-induced ICH. This protection coincided with AQP-4 upregulation in the brain. Kleindienst and colleagues produced TBI in rats by the CCI model (Kleindienst et al., 2013). They used the same experimental V1a receptor blocker (SR49059) after the injury and observed that the drug was protective against TBI-induced brain edema in rats. This protection also correlated with AQP-4 upregulation in the brain.

Regardless of the brain injury model, all studies report strong protective properties of V1a receptor blockers against brain edema. However, the role of V2 receptors in cerebrovascular physiology remains unclear. It has been demonstrated that conivaptan, being a blocker of both V1a and V2 receptors, influences AQP-2 in the kidneys (Li-Ng and Verbalis, 2009). Interaction between the renal tubular V2 receptors and AQP-2 has been reported to be necessary for the function of V2 receptors (Deen et al., 1994). It is yet to be demonstrated conivaptan’s protective effects against brain edema and BBB disruption are linked to AQP-4 in the brain. If interactions between AQP receptors and AQP-4 are confirmed in the brain, this finding will greatly advance neuroscience and open new avenues for medical research in the field of brain edema research.

Our recently published study (Zeynalov et al., 2015) offers the mixed V1a and V2 receptor blocker conivaptan as an alternative or, possibly supplemental, drug to the currently used therapeutic approaches to treat stroke-evoked brain edema. Results of our research can yield important knowledge about the role of the AVP system in the pathophysiology of stroke-induced brain edema. This study will also assist translation of experimental results into clinical practice, help improve therapeutic approaches, and address existing challenges in clinical management of stroke.

In summary, the AVP receptor blocker conivaptan may have a potential for alleviating post-ischemic brain edema and minimizing BBB disruption in patients after stroke. Although effects of conivaptan on vascular physiology are yet to be demonstrated, strong evidence suggests that blocking both V1a and V2 receptors improves overall recovery after ischemic brain injury regardless of SIADH presence. Extensive preclinical studies of conivaptan in the context of stroke and brain edema will provide a complete spectrum of newly discovered features of the drug and its role in pathophysiology of stroke.

Funding provided by the Swedish Medical Center to J. Paul Elliott, MD. Author Contributions: EZ-writing of the manuscript; SMJ-writing of the manuscript.

Emil Zeynalov*, Susan M. Jones
Swedish Medical Center, Neurotrauma Research Department Englewood, Englewood, CO, USA

*Correspondence to: Emil Zeynalov, M.D., emil.zeynalov@healthonecares.com.

Received: 2016-01-15
doi: 10.4103/1673-5374.179038
http://www.nrronline.org/

How to cite this article: Zeynalov E, Jones SM (2016) Recent advances and future directions in preclinical research of arginine-vasopressin (AVP) receptor blocker conivaptan in the context of stroke. Neural Regen Res 11(3):392-393.

References
Deen PM, Verdijk MA, Knoers NV, Wieringa B, Mommsen LA, van Os CH, van Oost BA (1994) Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 264:82-95.
Fenton RA, Moeller HR (2008) Recent discoveries in vasopressin-regulated aquaporin-2 trafficking. Prog Brain Res 170:571-579.
Hedna VS, Bidari S, Gubinick D, Ansari S, Satriotomo I, Khan AA, Qureshi AI (2014) Treatment of stroke related refractory brain edema using mixed vasopressin antagonist: a case report and review of the literature. BMC Neuro 14:213.
Holmes CI, Landry DW, Granton JT (2003) Science review: Vasopressin and the cardiovascular system part 1--receptor physiology. Crit Care 7:427-434.
Kleindienst A, Dunbar JG, Gilsson R, Marmarou A (2013) The role of vasopressin V1A receptors in cytotoxic brain edema formation following brain injury. Acta Neurochir (Wien) 155:151-164.
Li-Ng M, Verbalis JG (2009) Conivaptan: Evidence supporting its therapeutic use in hyponatremia. Core Evid 4:83-92.
Liu X, Nakayama S, Amiry-Moghaddam M, Ottersen OP, Bhardwaj A (2010) Arginine-vasopressin V1 but not V2 receptor antagonism modifies infarct volume, brain water content, and aquaporin 4 expression following experimental stroke. Neurocrit Care 12:124-131.
Manaenko A, Fatiali N, Khatibi NH, Lekic T, Hasegawa Y, Martin R, Tang I, Zhang JH (2011) Arginine-vasopressin V1a receptor inhibition improves neurological outcomes following an intracerebral hemorrhagic brain injury. Neurochem Int 58:542-548.
Raurin K, Trabold R, Brem C, Tergollii PA, Nlesnina N (2013) Arginine vasopressin V1a receptor-deficient mice have reduced brain edema and secondary brain damage following traumatic brain injury. J Neurotrauma 30:1442-1448.
Saleem S, Yousuf I, Gul A, Gupta S, Verma S (2014) Hyponatremia in stroke. Ann Indian Acad Neurol 17:55-57.
Zeynalov E, Jones SM, Seo JW, Snell LD, Elliott JP (2015) Arginine-vasopressin receptor blocker conivaptan reduces brain edema and blood-brain barrier disruption after experimental stroke in mice. PLoS One 10:e0136121.
Zeynalov E, Chen CH, Froehner SC, Adams ME, Ottersen OP, Amiry-Moghaddam M, Bhardwaj A (2008) The perivascular pool of aquaporin-4 mediates the effect of osmotherapy in postischemic cerebral edema. Crit Care Med 36:2634-2640.